Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $48.1 million.

  • OptimizeRx's Total Liabilities fell 527.46% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year decrease of 527.46%. This contributed to the annual value of $54.2 million for FY2024, which is 466.55% down from last year.
  • According to the latest figures from Q3 2025, OptimizeRx's Total Liabilities is $48.1 million, which was down 527.46% from $50.0 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Total Liabilities ranged from a high of $56.8 million in Q4 2023 and a low of $5.5 million during Q2 2023
  • Its 5-year average for Total Liabilities is $26.1 million, with a median of $8.5 million in 2022.
  • As far as peak fluctuations go, OptimizeRx's Total Liabilities crashed by 5451.72% in 2021, and later skyrocketed by 84124.65% in 2024.
  • Quarter analysis of 5 years shows OptimizeRx's Total Liabilities stood at $9.6 million in 2021, then dropped by 11.09% to $8.5 million in 2022, then skyrocketed by 565.32% to $56.8 million in 2023, then decreased by 4.67% to $54.2 million in 2024, then fell by 11.28% to $48.1 million in 2025.
  • Its last three reported values are $48.1 million in Q3 2025, $50.0 million for Q2 2025, and $51.5 million during Q1 2025.